Clascoterone 5% solution

Phase 3

Cassiopea SpA (CASP.SW)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Alopecia, Androgenetic

View Full Landscape

Drug Information

Target Indication

Alopecia, Androgenetic

Clinical Trial

NCT05910450

Last updated: 2/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA10/17/2025

Winlevi

Adults Winlevi is indicated for the treatment of acne vulgaris. Adolescents (from 12 to < 18 years of age) Winlevi is indicated for the treatment of facial acne vulgaris.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

CASP.SW

Cassiopea SpA

Biotechnology•Europe•International

Related Pipeline

CB-03-01 cream, 1%Phase 3

Acne Vulgaris

cortexolone 17α-propionatePhase 2

Acne Vulgaris

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts